DYNE THERAPEUTICS INC (DYN) Fundamental Analysis & Valuation

NASDAQ:DYN • US26818M1080

17.92 USD
-0.14 (-0.78%)
At close: Mar 13, 2026
17.99 USD
+0.07 (+0.39%)
After Hours: 3/13/2026, 8:22:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DYN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall DYN gets a fundamental rating of 2 out of 10. We evaluated DYN against 519 industry peers in the Biotechnology industry. The financial health of DYN is average, but there are quite some concerns on its profitability. DYN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. DYN Profitability Analysis

1.1 Basic Checks

  • DYN had negative earnings in the past year.
  • In the past year DYN has reported a negative cash flow from operations.
  • In the past 5 years DYN always reported negative net income.
  • In the past 5 years DYN always reported negative operating cash flow.
DYN Yearly Net Income VS EBIT VS OCF VS FCFDYN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -37.59%, DYN is in line with its industry, outperforming 59.54% of the companies in the same industry.
  • With a decent Return On Equity value of -45.90%, DYN is doing good in the industry, outperforming 67.05% of the companies in the same industry.
Industry RankSector Rank
ROA -37.59%
ROE -45.9%
ROIC N/A
ROA(3y)-75.48%
ROA(5y)-63.28%
ROE(3y)-118.25%
ROE(5y)-92.38%
ROIC(3y)N/A
ROIC(5y)N/A
DYN Yearly ROA, ROE, ROICDYN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • DYN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DYN Yearly Profit, Operating, Gross MarginsDYN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DYN Health Analysis

2.1 Basic Checks

  • DYN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DYN has been increased compared to 5 years ago.
  • Compared to 1 year ago, DYN has a worse debt to assets ratio.
DYN Yearly Shares OutstandingDYN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
DYN Yearly Total Debt VS Total AssetsDYN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 6.29 indicates that DYN is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 6.29, DYN is doing good in the industry, outperforming 75.34% of the companies in the same industry.
  • A Debt/Equity ratio of 0.15 indicates that DYN is not too dependend on debt financing.
  • DYN has a worse Debt to Equity ratio (0.15) than 63.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 6.29
ROIC/WACCN/A
WACCN/A
DYN Yearly LT Debt VS Equity VS FCFDYN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 22.25 indicates that DYN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 22.25, DYN belongs to the best of the industry, outperforming 96.53% of the companies in the same industry.
  • A Quick Ratio of 22.25 indicates that DYN has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 22.25, DYN belongs to the top of the industry, outperforming 96.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.25
Quick Ratio 22.25
DYN Yearly Current Assets VS Current LiabilitesDYN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DYN Growth Analysis

3.1 Past

  • The earnings per share for DYN have decreased by -5.67% in the last year.
EPS 1Y (TTM)-5.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • DYN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.13% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.88%
EPS Next 2Y6.8%
EPS Next 3Y12.74%
EPS Next 5Y23.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DYN Yearly Revenue VS EstimatesDYN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
DYN Yearly EPS VS EstimatesDYN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. DYN Valuation Analysis

4.1 Price/Earnings Ratio

  • DYN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DYN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYN Price Earnings VS Forward Price EarningsDYN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYN Per share dataDYN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • DYN's earnings are expected to grow with 12.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.8%
EPS Next 3Y12.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DYN Dividend Analysis

5.1 Amount

  • DYN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DYN Fundamentals: All Metrics, Ratios and Statistics

DYNE THERAPEUTICS INC

NASDAQ:DYN (3/13/2026, 8:22:02 PM)

After market: 17.99 +0.07 (+0.39%)

17.92

-0.14 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners107.16%
Inst Owner Change16.63%
Ins Owners0.47%
Ins Owner Change2.09%
Market Cap2.90B
Revenue(TTM)N/A
Net Income(TTM)-446.21M
Analysts84
Price Target41.48 (131.47%)
Short Float %12.65%
Short Ratio9.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.2%
Min EPS beat(2)2.28%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)-1.61%
Min EPS beat(4)-18.24%
Max EPS beat(4)10.13%
EPS beat(8)4
Avg EPS beat(8)-3.42%
EPS beat(12)4
Avg EPS beat(12)-7.98%
EPS beat(16)7
Avg EPS beat(16)-4.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)16.82%
EPS NQ rev (1m)1.68%
EPS NQ rev (3m)4.75%
EPS NY rev (1m)0.74%
EPS NY rev (3m)3.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)-3.54
EYN/A
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)-2.62
FCFYN/A
OCF(TTM)-2.5
OCFYN/A
SpS0
BVpS6.02
TBVpS6.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.59%
ROE -45.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.48%
ROA(5y)-63.28%
ROE(3y)-118.25%
ROE(5y)-92.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1010.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.25
Quick Ratio 22.25
Altman-Z 6.29
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)398.78%
Cap/Depr(5y)342.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
EPS Next Y6.88%
EPS Next 2Y6.8%
EPS Next 3Y12.74%
EPS Next 5Y23.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.34%
EBIT Next 3Y0.11%
EBIT Next 5YN/A
FCF growth 1Y-43.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.91%
OCF growth 3YN/A
OCF growth 5YN/A

DYNE THERAPEUTICS INC / DYN FAQ

Can you provide the ChartMill fundamental rating for DYNE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to DYN.


Can you provide the valuation status for DYNE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DYNE THERAPEUTICS INC (DYN). This can be considered as Overvalued.


What is the profitability of DYN stock?

DYNE THERAPEUTICS INC (DYN) has a profitability rating of 1 / 10.


What is the financial health of DYNE THERAPEUTICS INC (DYN) stock?

The financial health rating of DYNE THERAPEUTICS INC (DYN) is 5 / 10.


Can you provide the expected EPS growth for DYN stock?

The Earnings per Share (EPS) of DYNE THERAPEUTICS INC (DYN) is expected to grow by 6.88% in the next year.